알파-에르고크립틴

그림문자(GHS)

• 그림문자(GHS)

  

• 신호 어

  Warning

• 유해·위험 문구

  H302：삼키면 유해함

  H312：피부와 접촉하면 유해함

  H332：흡입하면 유해함

  H361：태아 또는 생식능력에 손상을 일으킬 것으로 의심됨

  H362：모유를 먹는 아이에게 유해할 수 있음

• 예방조치문구

  P201：사용 전 취급 설명서를 확보하시오.

  P202：모든 안전 조치 문구를 읽고 이해하기 전에는 취급하지 마시오.

  P260：분진·흄·가스·미스트·증기·...·스프레이를 흡입하지 마시오.

  P261：분진·흄·가스·미스트·증기·...·스프레이의 흡입을 피하시오.

  P263：임신·수유 기간에는 접촉하지 마시오.

  P264：취급 후에는 손을 철저히 씻으시오.

  P264：취급 후에는 손을 철저히 씻으시오.

  P270：이 제품을 사용할 때에는 먹거나, 마시거나 흡연하지 마시오.

  P271：옥외 또는 환기가 잘 되는 곳에서만 취급하시오.

  P280：보호장갑/보호의/보안경/안면보호구를 착용하시오.

  P281：요구되는 개인 보호구를 착용하시오

  P301+P312：삼켜서 불편함을 느끼면 의료기관(의사)의 진찰을 받으시오.

  P302+P352：피부에 묻으면 다량의 물로 씻으시오.

  P304+P340：흡입하면 신선한 공기가 있는 곳으로 옮기고 호흡하기 쉬운 자세로 안정을 취하시오.

  P308+P313：노출 또는 접촉이 우려되면 의학적인 조치· 조언를 구하시오.

  P312：불편함을 느끼면 의료기관(의사)의 진찰을 받으시오.

  P322：특정 조치(라벨의 … 참조)

  P330：입을 씻어내시오.

  P363：다시 사용전 오염된 의류는 세척하시오.

  P405：밀봉하여 저장하시오.

  P501：...에 내용물 / 용기를 폐기 하시오.

알파-에르고크립틴 화학적 특성, 용도, 생산

• 화학적 성질

  Pale Yellow Solid

• 용도

  An impurity of 2-Bromo α-Ergocriptine Mesylate (B682600).

• 정의

  ChEBI: Ergotaman bearing hydroxy, isopropyl, and 2-methylpropyl groups at the 12', 2' and 5' positions, respectively, and oxo groups at positions 3', 6', and 18. It is a natural ergot alkaloid. Ergocryptine discussed in the literature prior to 1967, when b ta-ergocryptine was separated from alpha-ergocryptine, is now referred to as alpha-ergocryptine.

• 일반 설명

  One of the biologically most important ergot alkaloids is α-ergocryptine. Its semisynthetic derivative, the so-called bromocryptine, is one of the most widely used drugs in this family (e.g., as a prolactin inhibitor or an anti-Parkinsonian)[2]. 

• Toxicology

  A study describes the metabolic changes observed in a dietary subacute toxicity experiment with the ergot alkaloid α-ergocryptine in Sprague±Dawley rats. The rats were fed 0, 4, 20, 100 or 500 mg ergocryptine/kg diet for 28±32 days (equal to 0, 0.36, 1.7, 8.9 and 60 mg ergocryptine/kg body weight/day for females and 0, 0.34, 1.4, 6.6 and 44 mg ergocryptine/kg body weight/day for males). Total cholesterol and high-density lipoprotein (HDL)-cholesterol was decreased dose-dependently in females, but the ratio HDL-cholesterol/total cholesterol was only decreased at 20 mg/kg body weight. Triglycerides and glucose concentrations were decreased in the highest dose groups of both sexes. Serum urea concentrations were increased in the 20, 100 and 500 mg/kg dose groups. Insulin, glucagon and liver glycogen were increased in the highest dose group at the end of the study when the animals were allowed to eat prior to blood sampling and necropsy. Prolactin, T4 and FT4 were decreased in the 20, 100 and 500 mg/kg dose groups of both sexes. Follicle-stimulating hormone (FSH) was decreased in the 20, 100 and 500 mg/kg female dose groups and luteinizing hormone (LH) was increased in the 20, 100 and 500 mg/kg male dose groups[1].

• Purification Methods

  It crystallises with solvent of crystallisation, from acetone, *benzene or methanol. [Stadler et al. Helv Chim Acta 52 1549 1969, Beilstein 25 III/IV 964, 27 II 860.]

알파-에르고크립틴 공급 업체

Global(72)Suppliers